Advertisement

David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Advertisement


Related Videos

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Peter Clark, MA, MD, FRCP: A Payer Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement



Jan
21
Today In Oncology
Patient-Reported Outcomes With Triplet Therapy for Newly Diagnosed Multiple Myeloma
Surgical Intervention May Offer Survival Advantage for Certain Patients With Metastatic Breast Cancer
Do Adult-Onset Cancer Survivors Have a Higher Risk of Developing a Subsequent Malignancy
Adjuvant Gefitinib vs Vinorelbine/Cisplatin in Stage II–IIIA EGFR-Mutant NSCLC
Study Finds Inflammation Due to Androgen-Deprivation Therapy May Contribute to Fatigue, Other Side Effects in Men With Prostate Cancer
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside